Commercial Excellence

2023 Global (Ex-US) Incentive Compensation Benchmarking Study

The sales representative’s role in the life sciences industry has evolved in recent years. With the pharma landscape becoming more dynamic, designing region-specific policies and strategies to drive customer success is increasingly important.  

Incentives are a proven way to drive sales rep behavior, and incentive compensation (IC) team leaders must be aware of the latest industry trends and region-specific best practices to design incentive plans that can drive sales force performance. Axtria conducted its 2023 Global (Ex-US) Incentive Compensation Benchmarking Study across life sciences organizations with global operations.

Key areas covered in the complete study include:

  • IC target pay variations by therapy, role, and geography
  • Common incentive plan design practices by therapy and geography
  • Commonly leveraged MBO types
  • Data sources used for incentive crediting
  • Pay mix variations by role, therapy, and region
  • Typical IC performance periods and reporting frequencies by therapy and region

EX_US

2023 Global (Ex-US) Incentive Compensation Benchmarking Study

Incentive Compensation Benchmarking Study (1)
Connect with our experts to schedule a personalized readout of the complete study

Recommended insights

2023 Global (Ex-US) Incentive Compensation

Report

Insights from Axtria Ignite 2025 - Making AI Matter: Unlocking Business Value in Life Sciences
2023 Global (Ex-US) Incentive Compensation

Article

The Future of Omnichannel Pharma Sales: Moving Beyond NBA to Drive HCP Engagement
2023 Global (Ex-US) Incentive Compensation

Case Study

Accelerating High-Impact Pharma Launches at Scale with Axtria